Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 77 | 2024 | 5649 | 9.410 |
Why?
|
Hematologic Neoplasms | 37 | 2024 | 1895 | 8.510 |
Why?
|
Palliative Care | 71 | 2024 | 3607 | 6.950 |
Why?
|
Terminal Care | 38 | 2024 | 1758 | 6.460 |
Why?
|
Quality of Life | 104 | 2024 | 13308 | 5.460 |
Why?
|
Caregivers | 31 | 2024 | 2224 | 4.480 |
Why?
|
Leukemia, Myeloid, Acute | 29 | 2024 | 3602 | 4.340 |
Why?
|
Hospice Care | 15 | 2023 | 692 | 4.230 |
Why?
|
Graft vs Host Disease | 25 | 2024 | 3025 | 3.390 |
Why?
|
Advance Care Planning | 15 | 2024 | 697 | 2.890 |
Why?
|
Neoplasms | 60 | 2024 | 22072 | 2.730 |
Why?
|
End Stage Liver Disease | 7 | 2024 | 353 | 2.280 |
Why?
|
Gastrointestinal Neoplasms | 15 | 2023 | 951 | 2.120 |
Why?
|
Adaptation, Psychological | 22 | 2024 | 2628 | 1.910 |
Why?
|
Depression | 39 | 2024 | 8044 | 1.780 |
Why?
|
Anxiety | 27 | 2024 | 4538 | 1.760 |
Why?
|
Transplantation Conditioning | 18 | 2023 | 1588 | 1.690 |
Why?
|
Affect | 11 | 2019 | 1480 | 1.640 |
Why?
|
Hospitalization | 31 | 2024 | 10790 | 1.580 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2024 | 1375 | 1.580 |
Why?
|
Humans | 282 | 2024 | 760621 | 1.250 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2024 | 357 | 1.210 |
Why?
|
Liver Diseases | 5 | 2024 | 1302 | 1.140 |
Why?
|
Stress, Psychological | 12 | 2024 | 4446 | 1.090 |
Why?
|
Stress Disorders, Post-Traumatic | 8 | 2021 | 4555 | 1.090 |
Why?
|
Disabled Persons | 6 | 2021 | 1223 | 1.090 |
Why?
|
Myelodysplastic Syndromes | 7 | 2020 | 1394 | 1.090 |
Why?
|
Digestive System Diseases | 3 | 2023 | 151 | 1.070 |
Why?
|
Hospices | 5 | 2020 | 256 | 1.060 |
Why?
|
Patient Preference | 9 | 2020 | 922 | 1.050 |
Why?
|
Confusion | 2 | 2018 | 279 | 1.040 |
Why?
|
Videotape Recording | 5 | 2022 | 337 | 1.000 |
Why?
|
Aged | 110 | 2024 | 169152 | 0.980 |
Why?
|
Immunotherapy, Adoptive | 7 | 2024 | 1454 | 0.970 |
Why?
|
Middle Aged | 113 | 2024 | 220352 | 0.940 |
Why?
|
Cross-Sectional Studies | 23 | 2024 | 25942 | 0.900 |
Why?
|
Stem Cell Transplantation | 6 | 2022 | 1599 | 0.900 |
Why?
|
Prognosis | 35 | 2024 | 29658 | 0.890 |
Why?
|
Inpatients | 7 | 2024 | 2581 | 0.880 |
Why?
|
Social Support | 5 | 2021 | 2145 | 0.840 |
Why?
|
Lymphoma | 7 | 2023 | 1898 | 0.830 |
Why?
|
Decision Making | 12 | 2021 | 3925 | 0.820 |
Why?
|
Family | 6 | 2023 | 3189 | 0.820 |
Why?
|
Pilot Projects | 20 | 2024 | 8555 | 0.820 |
Why?
|
Patient Acceptance of Health Care | 11 | 2023 | 3164 | 0.810 |
Why?
|
Male | 133 | 2024 | 359744 | 0.810 |
Why?
|
Female | 136 | 2024 | 391270 | 0.790 |
Why?
|
Natural Language Processing | 5 | 2023 | 1135 | 0.780 |
Why?
|
Resuscitation Orders | 3 | 2019 | 270 | 0.750 |
Why?
|
Burkitt Lymphoma | 1 | 2023 | 333 | 0.740 |
Why?
|
Information Literacy | 1 | 2020 | 11 | 0.740 |
Why?
|
Communication | 12 | 2024 | 3849 | 0.710 |
Why?
|
Lung Neoplasms | 19 | 2024 | 13262 | 0.700 |
Why?
|
Cardiopulmonary Resuscitation | 7 | 2019 | 1004 | 0.700 |
Why?
|
Needs Assessment | 4 | 2020 | 1139 | 0.660 |
Why?
|
Multiple Myeloma | 4 | 2022 | 5130 | 0.660 |
Why?
|
Comparative Effectiveness Research | 1 | 2024 | 718 | 0.650 |
Why?
|
Adult | 79 | 2024 | 219994 | 0.640 |
Why?
|
Physician-Patient Relations | 8 | 2024 | 3242 | 0.620 |
Why?
|
Electronics | 1 | 2020 | 315 | 0.610 |
Why?
|
Leukemia | 4 | 2022 | 1520 | 0.600 |
Why?
|
Medical Oncology | 8 | 2024 | 2313 | 0.590 |
Why?
|
Roseolovirus Infections | 1 | 2018 | 50 | 0.590 |
Why?
|
Genital Neoplasms, Female | 1 | 2023 | 533 | 0.580 |
Why?
|
Esophageal and Gastric Varices | 1 | 2019 | 208 | 0.580 |
Why?
|
Herpesvirus 6, Human | 1 | 2018 | 97 | 0.580 |
Why?
|
Meningoencephalitis | 1 | 2018 | 83 | 0.580 |
Why?
|
Lymphoma, Follicular | 1 | 2021 | 453 | 0.570 |
Why?
|
Patients | 4 | 2023 | 906 | 0.560 |
Why?
|
Goals | 3 | 2023 | 708 | 0.550 |
Why?
|
Fatigue | 5 | 2024 | 1544 | 0.550 |
Why?
|
Intensive Care Units | 6 | 2023 | 3736 | 0.540 |
Why?
|
Busulfan | 3 | 2017 | 258 | 0.540 |
Why?
|
Self Efficacy | 1 | 2020 | 630 | 0.540 |
Why?
|
Empathy | 1 | 2021 | 473 | 0.530 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 695 | 0.530 |
Why?
|
Hospital Mortality | 3 | 2019 | 5425 | 0.530 |
Why?
|
Transplantation, Homologous | 12 | 2024 | 4810 | 0.520 |
Why?
|
Arabinonucleosides | 1 | 2015 | 34 | 0.510 |
Why?
|
Adenine Nucleotides | 1 | 2015 | 111 | 0.510 |
Why?
|
Survivors | 7 | 2024 | 2375 | 0.500 |
Why?
|
Transplantation, Autologous | 6 | 2023 | 2116 | 0.500 |
Why?
|
Patient Education as Topic | 5 | 2024 | 2315 | 0.490 |
Why?
|
Attitude | 2 | 2020 | 777 | 0.490 |
Why?
|
Patient Readmission | 5 | 2024 | 3323 | 0.480 |
Why?
|
Patient Care Planning | 2 | 2019 | 908 | 0.470 |
Why?
|
Aged, 80 and over | 31 | 2024 | 58995 | 0.470 |
Why?
|
Communicable Disease Control | 1 | 2021 | 844 | 0.460 |
Why?
|
Retrospective Studies | 33 | 2024 | 80372 | 0.460 |
Why?
|
Decision Support Techniques | 4 | 2020 | 2001 | 0.460 |
Why?
|
Trust | 1 | 2018 | 532 | 0.440 |
Why?
|
Delirium | 2 | 2023 | 1663 | 0.440 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1791 | 0.430 |
Why?
|
Longitudinal Studies | 9 | 2024 | 14495 | 0.420 |
Why?
|
Glioma | 5 | 2022 | 3420 | 0.420 |
Why?
|
Liver Transplantation | 3 | 2024 | 2325 | 0.410 |
Why?
|
Immunocompromised Host | 1 | 2018 | 857 | 0.410 |
Why?
|
Patient Satisfaction | 7 | 2024 | 3448 | 0.400 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 1784 | 0.400 |
Why?
|
Referral and Consultation | 4 | 2019 | 3598 | 0.390 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2021 | 5251 | 0.390 |
Why?
|
Transplantation Immunology | 1 | 2013 | 532 | 0.380 |
Why?
|
Prospective Studies | 18 | 2023 | 54303 | 0.360 |
Why?
|
Head and Neck Neoplasms | 2 | 2022 | 2882 | 0.360 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4902 | 0.360 |
Why?
|
Patient Discharge | 4 | 2024 | 3476 | 0.360 |
Why?
|
Neurotoxicity Syndromes | 3 | 2024 | 299 | 0.360 |
Why?
|
Central Nervous System Neoplasms | 4 | 2023 | 916 | 0.360 |
Why?
|
Multicenter Studies as Topic | 3 | 2024 | 1722 | 0.360 |
Why?
|
Intubation, Intratracheal | 2 | 2016 | 1328 | 0.350 |
Why?
|
Perception | 3 | 2022 | 1195 | 0.340 |
Why?
|
Feasibility Studies | 5 | 2024 | 5201 | 0.340 |
Why?
|
Sarcopenia | 3 | 2021 | 372 | 0.340 |
Why?
|
Liver Cirrhosis | 4 | 2024 | 1931 | 0.330 |
Why?
|
Length of Stay | 5 | 2022 | 6479 | 0.330 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2021 | 2003 | 0.310 |
Why?
|
Patient Admission | 1 | 2016 | 1386 | 0.310 |
Why?
|
Personal Satisfaction | 2 | 2024 | 643 | 0.310 |
Why?
|
Death | 3 | 2021 | 678 | 0.310 |
Why?
|
Health Communication | 2 | 2022 | 212 | 0.300 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 13630 | 0.300 |
Why?
|
Acute Disease | 6 | 2024 | 7269 | 0.300 |
Why?
|
Treatment Outcome | 22 | 2024 | 65017 | 0.300 |
Why?
|
Hematology | 2 | 2023 | 241 | 0.300 |
Why?
|
United States | 22 | 2024 | 72461 | 0.300 |
Why?
|
fms-Like Tyrosine Kinase 3 | 3 | 2016 | 495 | 0.300 |
Why?
|
Hematologic Diseases | 2 | 2023 | 496 | 0.300 |
Why?
|
Primary Myelofibrosis | 2 | 2023 | 210 | 0.290 |
Why?
|
Pancreatic Neoplasms | 2 | 2022 | 5351 | 0.290 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2299 | 0.280 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 1547 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 10344 | 0.260 |
Why?
|
Bone Marrow Transplantation | 4 | 2020 | 2693 | 0.250 |
Why?
|
Quality Improvement | 1 | 2020 | 3836 | 0.250 |
Why?
|
Qualitative Research | 6 | 2023 | 2963 | 0.240 |
Why?
|
Breast Neoplasms | 7 | 2022 | 21025 | 0.240 |
Why?
|
Massachusetts | 6 | 2021 | 8803 | 0.240 |
Why?
|
Antigens, CD19 | 2 | 2024 | 424 | 0.230 |
Why?
|
Attitude to Health | 3 | 2019 | 2029 | 0.230 |
Why?
|
Melanoma | 3 | 2021 | 5697 | 0.230 |
Why?
|
Depressive Disorder | 1 | 2017 | 3726 | 0.230 |
Why?
|
Physicians | 2 | 2019 | 4591 | 0.220 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4319 | 0.220 |
Why?
|
Niacinamide | 2 | 2016 | 414 | 0.220 |
Why?
|
Patient Participation | 4 | 2020 | 1439 | 0.210 |
Why?
|
Brain Neoplasms | 4 | 2023 | 8986 | 0.210 |
Why?
|
Disease Management | 4 | 2021 | 2514 | 0.210 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2023 | 296 | 0.200 |
Why?
|
Renal Replacement Therapy | 1 | 2024 | 281 | 0.200 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 529 | 0.200 |
Why?
|
Bone Marrow | 3 | 2020 | 2912 | 0.200 |
Why?
|
Critical Illness | 1 | 2015 | 2709 | 0.200 |
Why?
|
Checklist | 2 | 2021 | 827 | 0.190 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2022 | 142 | 0.190 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2020 | 3986 | 0.190 |
Why?
|
Efficiency | 2 | 2024 | 477 | 0.190 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2022 | 164 | 0.180 |
Why?
|
Activities of Daily Living | 5 | 2021 | 2417 | 0.180 |
Why?
|
Age Factors | 8 | 2024 | 18416 | 0.180 |
Why?
|
Documentation | 3 | 2023 | 893 | 0.180 |
Why?
|
Early Detection of Cancer | 5 | 2021 | 3202 | 0.180 |
Why?
|
Chimerism | 1 | 2021 | 155 | 0.180 |
Why?
|
Leucovorin | 1 | 2022 | 641 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 298 | 0.180 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7818 | 0.170 |
Why?
|
Wheelchairs | 1 | 2020 | 78 | 0.170 |
Why?
|
Cost of Illness | 4 | 2024 | 1940 | 0.170 |
Why?
|
Mobility Limitation | 2 | 2021 | 402 | 0.170 |
Why?
|
Immunoconjugates | 2 | 2018 | 949 | 0.170 |
Why?
|
Cytarabine | 2 | 2019 | 696 | 0.170 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8552 | 0.170 |
Why?
|
Telemedicine | 3 | 2022 | 3018 | 0.170 |
Why?
|
Survival Analysis | 5 | 2024 | 10182 | 0.170 |
Why?
|
T-Lymphocytes | 5 | 2024 | 10181 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 1628 | 0.170 |
Why?
|
Remission Induction | 4 | 2017 | 2392 | 0.160 |
Why?
|
Cachexia | 1 | 2020 | 198 | 0.160 |
Why?
|
Ambulatory Care | 3 | 2022 | 2781 | 0.160 |
Why?
|
Self Care | 1 | 2024 | 793 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 466 | 0.160 |
Why?
|
Boston | 3 | 2021 | 9280 | 0.160 |
Why?
|
Foscarnet | 1 | 2018 | 35 | 0.150 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3696 | 0.150 |
Why?
|
Graft vs Host Reaction | 1 | 2018 | 103 | 0.150 |
Why?
|
Vaginal Smears | 1 | 2021 | 495 | 0.150 |
Why?
|
Psychometrics | 4 | 2021 | 3051 | 0.150 |
Why?
|
Respiration, Artificial | 2 | 2021 | 2622 | 0.150 |
Why?
|
Young Adult | 12 | 2023 | 58741 | 0.150 |
Why?
|
New England | 1 | 2020 | 1050 | 0.140 |
Why?
|
Colorectal Neoplasms | 4 | 2021 | 6853 | 0.140 |
Why?
|
Continuity of Patient Care | 2 | 2024 | 1066 | 0.140 |
Why?
|
Socioeconomic Factors | 4 | 2021 | 7806 | 0.140 |
Why?
|
Fluorouracil | 1 | 2022 | 1631 | 0.140 |
Why?
|
Employment | 1 | 2023 | 1112 | 0.140 |
Why?
|
Tracheostomy | 1 | 2021 | 425 | 0.140 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2019 | 305 | 0.140 |
Why?
|
Pandemics | 6 | 2022 | 8624 | 0.140 |
Why?
|
Anthracyclines | 1 | 2019 | 283 | 0.140 |
Why?
|
Chronic Disease | 3 | 2018 | 9287 | 0.140 |
Why?
|
Organ Specificity | 2 | 2020 | 1955 | 0.140 |
Why?
|
Attitude of Health Personnel | 3 | 2019 | 3865 | 0.140 |
Why?
|
Cohort Studies | 5 | 2022 | 41335 | 0.140 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 609 | 0.130 |
Why?
|
Mass Screening | 2 | 2024 | 5423 | 0.130 |
Why?
|
Geriatric Assessment | 2 | 2023 | 1405 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 11712 | 0.130 |
Why?
|
Logistic Models | 4 | 2020 | 13314 | 0.130 |
Why?
|
Bacteremia | 2 | 2020 | 980 | 0.130 |
Why?
|
Lymphoma, B-Cell | 1 | 2022 | 935 | 0.130 |
Why?
|
Self Report | 5 | 2022 | 3711 | 0.130 |
Why?
|
Cultural Competency | 1 | 2019 | 294 | 0.130 |
Why?
|
Quality of Health Care | 2 | 2024 | 4360 | 0.130 |
Why?
|
Actigraphy | 1 | 2019 | 518 | 0.130 |
Why?
|
Monitoring, Ambulatory | 1 | 2019 | 353 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 180 | 0.130 |
Why?
|
Severity of Illness Index | 5 | 2020 | 15840 | 0.130 |
Why?
|
Outpatients | 1 | 2023 | 1607 | 0.130 |
Why?
|
Delivery of Health Care | 3 | 2024 | 5325 | 0.120 |
Why?
|
Physical Fitness | 1 | 2019 | 732 | 0.120 |
Why?
|
Immunotherapy | 2 | 2021 | 4642 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 2 | 2015 | 1164 | 0.120 |
Why?
|
Waiting Lists | 1 | 2019 | 763 | 0.120 |
Why?
|
Religion | 1 | 2017 | 376 | 0.120 |
Why?
|
Autopsy | 1 | 2018 | 1007 | 0.110 |
Why?
|
Time Factors | 5 | 2019 | 40165 | 0.110 |
Why?
|
Medication Adherence | 2 | 2023 | 2165 | 0.110 |
Why?
|
Regression Analysis | 2 | 2021 | 6360 | 0.110 |
Why?
|
Odds Ratio | 4 | 2019 | 9716 | 0.110 |
Why?
|
Disease-Free Survival | 4 | 2017 | 6828 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2018 | 1832 | 0.110 |
Why?
|
Video Recording | 2 | 2016 | 955 | 0.110 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39261 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2536 | 0.110 |
Why?
|
Health Services Accessibility | 2 | 2021 | 5397 | 0.110 |
Why?
|
Emotions | 3 | 2020 | 2734 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1231 | 0.100 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1056 | 0.100 |
Why?
|
Managed Care Programs | 1 | 2018 | 939 | 0.100 |
Why?
|
Sexual Behavior | 2 | 2021 | 2086 | 0.100 |
Why?
|
Anemia, Sickle Cell | 1 | 2020 | 1056 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2019 | 1131 | 0.100 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2018 | 708 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1941 | 0.100 |
Why?
|
Nursing Homes | 1 | 2019 | 1082 | 0.100 |
Why?
|
Blood Transfusion | 1 | 2018 | 1328 | 0.100 |
Why?
|
Heart Failure | 1 | 2016 | 11847 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 652 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 754 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5643 | 0.100 |
Why?
|
Internet | 1 | 2023 | 3078 | 0.100 |
Why?
|
Hospitals, Teaching | 1 | 2016 | 1166 | 0.090 |
Why?
|
Health Expenditures | 1 | 2024 | 2362 | 0.090 |
Why?
|
Models, Immunological | 1 | 2013 | 513 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2018 | 1535 | 0.090 |
Why?
|
Adolescent | 5 | 2024 | 87810 | 0.090 |
Why?
|
Geriatrics | 1 | 2015 | 387 | 0.090 |
Why?
|
Signal Transduction | 2 | 2013 | 23376 | 0.090 |
Why?
|
Electronic Health Records | 4 | 2021 | 4775 | 0.090 |
Why?
|
Research | 2 | 2017 | 1974 | 0.090 |
Why?
|
Sex Characteristics | 2 | 2018 | 2629 | 0.090 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2017 | 6015 | 0.090 |
Why?
|
Exercise Therapy | 1 | 2017 | 919 | 0.090 |
Why?
|
Pain | 3 | 2022 | 5066 | 0.090 |
Why?
|
Cyclophosphamide | 3 | 2023 | 2221 | 0.090 |
Why?
|
Teaching | 1 | 2017 | 1169 | 0.090 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12159 | 0.090 |
Why?
|
Mammography | 1 | 2021 | 2427 | 0.090 |
Why?
|
Consensus | 1 | 2019 | 3113 | 0.090 |
Why?
|
Interpersonal Relations | 1 | 2017 | 1428 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 936 | 0.090 |
Why?
|
Antidepressive Agents | 2 | 2020 | 2890 | 0.080 |
Why?
|
Survival Rate | 4 | 2018 | 12808 | 0.080 |
Why?
|
Weight Loss | 1 | 2021 | 2686 | 0.080 |
Why?
|
Models, Statistical | 1 | 2024 | 5075 | 0.080 |
Why?
|
Tissue Donors | 1 | 2019 | 2313 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3618 | 0.080 |
Why?
|
Databases, Factual | 3 | 2019 | 8035 | 0.080 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2009 | 90 | 0.080 |
Why?
|
Muscle, Skeletal | 2 | 2021 | 4925 | 0.080 |
Why?
|
Body Composition | 1 | 2018 | 2419 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4283 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3388 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9276 | 0.080 |
Why?
|
Risk Factors | 3 | 2020 | 74359 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2022 | 2290 | 0.070 |
Why?
|
Recurrence | 3 | 2024 | 8482 | 0.070 |
Why?
|
Lung | 2 | 2023 | 9994 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 3763 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3725 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2471 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8056 | 0.070 |
Why?
|
Societies, Medical | 1 | 2018 | 3905 | 0.070 |
Why?
|
Vidarabine | 2 | 2019 | 336 | 0.070 |
Why?
|
Therapeutics | 1 | 2006 | 114 | 0.070 |
Why?
|
Substance-Related Disorders | 1 | 2022 | 4371 | 0.070 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11152 | 0.070 |
Why?
|
Truth Disclosure | 1 | 2010 | 432 | 0.070 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2023 | 929 | 0.060 |
Why?
|
Diagnosis | 1 | 2006 | 157 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2018 | 3061 | 0.060 |
Why?
|
Antigens, CD7 | 1 | 2024 | 30 | 0.060 |
Why?
|
Anxiety Disorders | 1 | 2016 | 2714 | 0.060 |
Why?
|
Educational Status | 3 | 2019 | 2515 | 0.060 |
Why?
|
Nanoparticles | 2 | 2007 | 1943 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4215 | 0.060 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2024 | 45 | 0.060 |
Why?
|
Dendrimers | 1 | 2004 | 71 | 0.060 |
Why?
|
Gold | 1 | 2007 | 484 | 0.060 |
Why?
|
Health Personnel | 1 | 2017 | 3310 | 0.060 |
Why?
|
Hepatorenal Syndrome | 1 | 2024 | 76 | 0.060 |
Why?
|
Patient-Centered Care | 2 | 2024 | 1416 | 0.050 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 830 | 0.050 |
Why?
|
Internal Medicine | 1 | 2010 | 1048 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8469 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12965 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
Bereavement | 1 | 2006 | 307 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12531 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2023 | 8547 | 0.050 |
Why?
|
Interviews as Topic | 2 | 2021 | 2659 | 0.050 |
Why?
|
Interdisciplinary Studies | 1 | 2021 | 86 | 0.050 |
Why?
|
Incidence | 4 | 2023 | 21392 | 0.050 |
Why?
|
Cancer Care Facilities | 1 | 2023 | 424 | 0.050 |
Why?
|
Research Design | 3 | 2024 | 6180 | 0.050 |
Why?
|
Self-Help Devices | 1 | 2021 | 62 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2021 | 26181 | 0.040 |
Why?
|
Program Evaluation | 2 | 2020 | 2493 | 0.040 |
Why?
|
Mind-Body Therapies | 1 | 2023 | 265 | 0.040 |
Why?
|
Ohio | 1 | 2021 | 333 | 0.040 |
Why?
|
Social Work | 1 | 2021 | 158 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2020 | 165 | 0.040 |
Why?
|
Guilt | 1 | 2020 | 96 | 0.040 |
Why?
|
New York | 1 | 2022 | 875 | 0.040 |
Why?
|
Methotrexate | 2 | 2017 | 1719 | 0.040 |
Why?
|
Knowledge | 1 | 2020 | 176 | 0.040 |
Why?
|
Pneumonia, Aspiration | 1 | 2019 | 146 | 0.040 |
Why?
|
Whole-Body Irradiation | 1 | 2019 | 433 | 0.040 |
Why?
|
Child | 3 | 2021 | 79806 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3334 | 0.040 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1392 | 0.040 |
Why?
|
Dehydration | 1 | 2019 | 216 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 312 | 0.040 |
Why?
|
Melphalan | 1 | 2019 | 420 | 0.040 |
Why?
|
Hinduism | 1 | 2017 | 14 | 0.040 |
Why?
|
Veterans Health | 1 | 2019 | 216 | 0.040 |
Why?
|
Morals | 1 | 2021 | 289 | 0.040 |
Why?
|
Buddhism | 1 | 2017 | 23 | 0.040 |
Why?
|
Judaism | 1 | 2017 | 31 | 0.040 |
Why?
|
Christianity | 1 | 2017 | 48 | 0.040 |
Why?
|
Thiotepa | 1 | 2017 | 66 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 377 | 0.040 |
Why?
|
Home Care Services | 1 | 2024 | 654 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2019 | 369 | 0.040 |
Why?
|
Suicide, Assisted | 1 | 2017 | 69 | 0.040 |
Why?
|
Islam | 1 | 2017 | 71 | 0.030 |
Why?
|
Spleen | 1 | 2023 | 2298 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1998 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1334 | 0.030 |
Why?
|
Hawaii | 1 | 2016 | 101 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 956 | 0.030 |
Why?
|
Professional-Family Relations | 1 | 2020 | 495 | 0.030 |
Why?
|
Mucositis | 1 | 2017 | 108 | 0.030 |
Why?
|
Psychological Tests | 1 | 2018 | 639 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 24123 | 0.030 |
Why?
|
Mutation | 4 | 2021 | 29932 | 0.030 |
Why?
|
Mental Health | 2 | 2022 | 3213 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 643 | 0.030 |
Why?
|
Longevity | 1 | 2022 | 1050 | 0.030 |
Why?
|
Dementia | 1 | 2009 | 2649 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2017 | 877 | 0.030 |
Why?
|
Psychotherapy | 1 | 2023 | 1640 | 0.030 |
Why?
|
Dacarbazine | 1 | 2017 | 560 | 0.030 |
Why?
|
Glioblastoma | 1 | 2009 | 3484 | 0.030 |
Why?
|
Antigens, CD | 1 | 2024 | 4000 | 0.030 |
Why?
|
Renal Insufficiency | 1 | 2019 | 820 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2020 | 2698 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 814 | 0.030 |
Why?
|
Research Report | 1 | 2016 | 370 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2016 | 791 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1677 | 0.030 |
Why?
|
SEER Program | 1 | 2018 | 1530 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2022 | 1801 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2024 | 1939 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3839 | 0.020 |
Why?
|
Tissue Distribution | 2 | 2007 | 2262 | 0.020 |
Why?
|
Family Health | 1 | 2016 | 1257 | 0.020 |
Why?
|
Syndrome | 1 | 2018 | 3280 | 0.020 |
Why?
|
Proxy | 1 | 2012 | 148 | 0.020 |
Why?
|
Tacrolimus | 1 | 2015 | 733 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1869 | 0.020 |
Why?
|
Fear | 1 | 2020 | 1462 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2053 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7475 | 0.020 |
Why?
|
Aftercare | 1 | 2017 | 916 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 1999 | 0.020 |
Why?
|
Curriculum | 2 | 2017 | 3718 | 0.020 |
Why?
|
Motivation | 1 | 2020 | 1993 | 0.020 |
Why?
|
Illinois | 1 | 2010 | 118 | 0.020 |
Why?
|
Internship and Residency | 1 | 2010 | 5870 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 3016 | 0.020 |
Why?
|
Health Promotion | 1 | 2021 | 2206 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2017 | 1403 | 0.020 |
Why?
|
Pain Measurement | 1 | 2019 | 3528 | 0.020 |
Why?
|
Graft Rejection | 1 | 2021 | 4426 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2022 | 15697 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2131 | 0.020 |
Why?
|
Sirolimus | 1 | 2015 | 1547 | 0.020 |
Why?
|
Education | 1 | 2010 | 534 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2932 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5877 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6544 | 0.020 |
Why?
|
Patient Care Team | 1 | 2017 | 2511 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20080 | 0.020 |
Why?
|
Sepsis | 1 | 2019 | 2592 | 0.020 |
Why?
|
Animals | 3 | 2013 | 167963 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10551 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11345 | 0.010 |
Why?
|
Exercise | 1 | 2021 | 5787 | 0.010 |
Why?
|
Terminally Ill | 1 | 2006 | 240 | 0.010 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2138 | 0.010 |
Why?
|
Health Status | 1 | 2017 | 4081 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10547 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9631 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 4550 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 3075 | 0.010 |
Why?
|
Particle Size | 1 | 2007 | 1644 | 0.010 |
Why?
|
Choice Behavior | 1 | 2009 | 821 | 0.010 |
Why?
|
Educational Measurement | 1 | 2010 | 1248 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7408 | 0.010 |
Why?
|
Brachytherapy | 1 | 2009 | 1238 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6786 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6238 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5791 | 0.010 |
Why?
|
Mice, Nude | 1 | 2007 | 3607 | 0.010 |
Why?
|
Melanoma, Experimental | 1 | 2004 | 562 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2009 | 1660 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 12914 | 0.010 |
Why?
|
Radiosurgery | 1 | 2009 | 1343 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20509 | 0.010 |
Why?
|
Clinical Competence | 1 | 2010 | 4783 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 16939 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2007 | 22023 | 0.010 |
Why?
|
Mice | 1 | 2007 | 81208 | 0.000 |
Why?
|